Results 191 to 200 of about 212,465 (393)

Neuropeptide Y receptor interactions regulate its mitogenic activity. [PDF]

Neuropeptides, 2019
Czarnecka M, Lu C, Pons J, Maheswaran I, Ciborowski P, Zhang L, Cheema A, Kitlinska J.   +7 more
europepmc   +1 more source

The dark sides of the GPCR tree ‐ research progress on understudied GPCRs

British Journal of Pharmacology, EarlyView.
Abstract A large portion of the human GPCRome is still in the dark and understudied, consisting even of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion GPCRs, Frizzleds and taste receptors. However, it is undeniable that these GPCRs bring an untapped therapeutic potential that should be explored further.
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte   +10 more
wiley   +1 more source

Evidence That the Inhibition of Luteinizing Hormone Secretion Exerted by Central Administration of Neuropeptide Y (NPY) in the Rat Is Predominantly Mediated by the NPY-Y5 Receptor Subtype1

, 1999
Paula Raposinho, Pierre Broqua, Dominique D. Pierroz, A. H. S. HAYWARD, Yvan Dumont, Rémi Quirion, Jean‐Louis Junien, Michel L. Aubert   +7 more
openalex   +1 more source

Small-Molecule Agonists of Ae. aegypti Neuropeptide Y Receptor Block Mosquito Biting. [PDF]

Cell, 2019
Duvall LB, Ramos-Espiritu L, Barsoum KE, Glickman JF, Vosshall LB.   +4 more
europepmc   +1 more source

Progress on the development of Class A GPCR‐biased ligands

British Journal of Pharmacology, EarlyView.
Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales, Magdalena M. Scharf, Marcel Bermudez, Attila Egyed, Rafael Franco, Olivia K. Hansen, Nadine Jagerovic, Jan Jakubík, György M. Keserű, Dóra Judit Kiss, Pawel Kozielewicz, Olav Larsen, Maria Majellaro, Ana Mallo‐Abreu, Gemma Navarro, Rubén Prieto‐Díaz, Mette M. Rosenkilde, Eddy Sotelo, Holger Stark, Tobias Werner, Laura M. Wingler   +20 more
wiley   +1 more source

Adrenalectomy reduces neuropeptide Y–induced insulin release and NPY receptor expression in the rat ventromedial hypothalamus [PDF]

, 2000
Todd Wisialowski, Rachel M.C. Parker, Elaine Preston, Amanda Sainsbury, Edward W. Kraegen, Herbert Herzog, Gregory Cooney   +6 more
openalex   +1 more source

Characterisation of neurogenic lipolytic responses in white adipose tissue ex vivo

British Journal of Pharmacology, Volume 182, Issue 9, Page 1975-1988, May 2025.
Background and Purpose Dysfunction of the autonomic nervous system is associated with cardiovascular dysfunction, including metabolic syndrome and obesity. Understanding mechanisms of neurogenic control of white adipose tissue is key to understanding adipose physiology and pathophysiology, though there is limited research exploring this in adipose ...
Kayleigh E. Goddard, Samuel J. Fountain
wiley   +1 more source

Effects of a selective neuropeptide Y Y₁ receptor antagonist BIBP 3226 on double peaked vasoconstrictor responses to periarterial nerve stimulation in canine splenic arteries [PDF]

, 2000
Xiaoping Yang, Shigetoshi Chiba
openalex   +1 more source

Molecular cloning and characterization of an invertebrate homologue of a neuropeptide Y receptor

European Journal of Neuroscience, 1998
C. Tensen, K. J. Cox, J. Burke, R. Leurs, R. C. van der Schors, W. Geraerts, E. Vreugdenhil, Harm Van Heerikhuizen1   +7 more
semanticscholar   +1 more source

Cannabidiol dose dependently reduces alcohol intake in mice via a non‐5‐HT1A receptor mechanism: Exploration of other potential receptor targets

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Binge drinking is a risky pattern of alcohol intake and a major predictor of alcohol use disorder (AUD). Current AUD medications have limited efficacy and poor patient compliance, calling for more effective therapeutics.
Connie J. Badolato, Erin A. Lynch, Jonathon C. Arnold, Iain S. McGregor, Michael T. Bowen   +4 more
wiley   +1 more source